ARC-T Cells Plus SPRX002

Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up

Arms / Cohorts

Experimental:CD123-Specific Adapter (SPRX002) + Universal CAR-Modified T Cell (ARC-T Cells)

Status
Status not available
Overview
Overview not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Am I Eligible(888) 803-1766

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.